| Project/Area Number |
20591620
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
SUDA Kosuke Chiba University, 医学部附属病院, 助教 (50400908)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHITOMI Hideyuki 千葉大学, 医学部附属病院, 助教 (60375631)
TAKANO Shigetsugu 千葉大学, 医学部附属病院, 助教 (20436380)
KIMURA Fumio 千葉大学, 大学院・医学研究院, 准教授 (70334208)
MIYAZAKI Masaru 千葉大学, 大学院・医学研究院, 教授 (70166156)
SUZUKI Daisuke 千葉大学, 医学部附属病院, 医員 (90422229)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 膵臓外科学 / ApoC-1蛋白 / Protein Chip System / 膵癌細胞株 / 膵癌発育進展 / ProteinChip System |
|---|
| Research Abstract |
Pancreatic cancer still remains one of the most lethal diseases with increasing incidence. We recently identified Apolipoprotein C-1 (ApoC-1) as the serum biomarker for pancreatic cancer by serum protein profiling using surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS). The purpose of this study is to confirm whether serum ApoC-1 levels of patients with pancreatic cancer were a valuable marker using convenient ELISA method, and also whether ApoC-1 expression in resected pancreatic cancer tissue correlates with prognosis of patients after surgery.
We analyzed ApoC-1 serum level of 32 patients by two proteomic approaches. We also investigate whether ApoC-1 positive expression in resected tissues of patients with pancreatic cancer showed meaningful results in clinical outcome.
ApoC-1 serum levels were significantly decreased in compared preoperative and postoperative serum of patients both SELDI analysis and ELISA method. ApoC-1 levels of pancreatic cancer patients are significantly higher than that of patients with benign pancreatic disease by ELISA method. Furthermore, the immunohistochemical staining of ApoC-1 indicated that overexpression of ApoC-1 in resected pancreatic cancer tissues showed poor prognosis of patients (log rank-test ; P<0.038).
These results suggested that ApoC-1 positive expression was possible to predict poor prognosis of pancreatic cancer patients after surgery.
|
